For lung cancer, a novel study demonstrated that EVs derived from human primary CD8+ T cells, containing interleukin-2 and cetuximab, exhibited enhanced antitumor activity and targeting specificity against lung cancer cells, presenting a promising therapeutic strategy [146]. This evidence concerns the gene CD8A and lung cancer.